» Articles » PMID: 27903423

Cytotoxicity of Trans-chalcone and Licochalcone A Against Breast Cancer Cells is Due to Apoptosis Induction and Cell Cycle Arrest

Overview
Date 2016 Dec 2
PMID 27903423
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Chalcones are precursors of flavonoids that exhibit structural heterogeneity and potential antitumor activity. The objective of this study was to characterize the cytotoxicity of trans-chalcone and licochalcone A (LicoA) against a breast cancer cell line (MCF-7) and normal murine fibroblasts (3T3). Also the mechanisms of the anti-cancer activity of these two compounds were studied. The alkaline comet assay revealed dose-dependent genotoxicity, which was more responsive against the tumor cell line, compared to the 3T3 mouse fibroblast cell line. Flow cytometry showed that the two chalcones caused the cell cycle arrest in the G1 phase and induced apoptosis in MCF-7 cells. Using PCR Array, we found that trans-chalcone and LicoA trigger apoptosis mediated by the intrinsic pathway as demonstrated by the inhibition of Bcl-2 and induction of Bax. In western blot assay, the two chalcones reduced the expression of cell death-related proteins such as Bcl-2 and cyclin D1 and promoted the cleavage of PARP. However, only trans-chalcone induced the expression of the CIDEA gene and protein in these two experiments. Furthermore, transient transfections of MCF-7 using a construction of a promoter-luciferase vector showed that trans-chalcone induced the expression of the CIDEA promoter activity in 24 and 48h. In conclusion, the results showed that trans-chalcone promoted high induction of the CIDEA promoter gene and protein, which is related to DNA fragmentation during apoptosis.

Citing Articles

Computational investigation of naturally occurring anticancer agents in regulating Hedgehog pathway proteins.

Pai R, Sirigiri D, Malempati R, Vinjamuri S PLoS One. 2024; 19(12):e0311307.

PMID: 39625914 PMC: 11614240. DOI: 10.1371/journal.pone.0311307.


Licochalcone A: a review of its pharmacology activities and molecular mechanisms.

Liu M, Du Y, Gao D Front Pharmacol. 2024; 15:1453426.

PMID: 39188947 PMC: 11345200. DOI: 10.3389/fphar.2024.1453426.


Potential Anti-Tumorigenic Properties of Diverse Medicinal Plants against the Majority of Common Types of Cancer.

Albahri G, Badran A, Abdel Baki Z, Alame M, Hijazi A, Daou A Pharmaceuticals (Basel). 2024; 17(5).

PMID: 38794144 PMC: 11124340. DOI: 10.3390/ph17050574.


The therapeutic effect of traditional Chinese medicine on breast cancer through modulation of the Wnt/β-catenin signaling pathway.

Li H, Li J, Zhang Y, Zhao C, Ge J, Sun Y Front Pharmacol. 2024; 15:1401979.

PMID: 38783943 PMC: 11111876. DOI: 10.3389/fphar.2024.1401979.


The role of CSTF2 in cancer: from technology to clinical application.

Ding J, Su Y, Liu Y, Xu Y, Yang D, Wang X Cell Cycle. 2024; 22(23-24):2622-2636.

PMID: 38166492 PMC: 10936678. DOI: 10.1080/15384101.2023.2299624.